Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting
02 nov. 2023 09h01 HE
|
Shattuck Labs, Inc.
– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile – AUSTIN, Texas and DURHAM, N.C., Nov. 02, 2023...
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
10 août 2023 16h00 HE
|
Shattuck Labs, Inc.
– Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting,...
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
25 mai 2023 17h15 HE
|
Shattuck Labs, Inc.
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose – ...
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
09 mai 2023 16h00 HE
|
Shattuck Labs, Inc.
— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual...
Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
03 avr. 2023 07h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 03, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
16 mars 2023 08h31 HE
|
Shattuck Labs, Inc.
– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease – AUSTIN,...
Shattuck Labs Announces Participation in Upcoming March Conferences
01 mars 2023 07h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
23 févr. 2023 16h30 HE
|
Shattuck Labs, Inc.
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer – – Dosed patients in first combination cohort with...
Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
16 févr. 2023 07h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference
09 févr. 2023 06h01 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...